Press Releases

afabicin (Debio 1450) afabicin (Debio 1450) ABSSSI afabicin (Debio 1450) Bone & joint infections CARB-X Clinical Trials CPP cyclosporin A Debio 0123 Debio 025 Debio 0507 Debio 0513 Debio 0517 Debio 0614 (istaroxime) Debio 0615 Debio 0617 Debio 0719 Debio 0824 Debio 0826 Debio 0827 Debio 0928 Debio 0929 Debio 0930 Debio 0931 Debio 0932 NSCLS Debio 0932 RCC Debio 1036 Debio 1124 Debio 1141 Debio 1142 Debio 1143 Debio 1143 Head & neck cancer Debio 1143 NSCLC Debio 1143 Ovarian cancer Debio 1143 selected solid tumors Debio 1143 with pembrolizumab Debio 1144 Debio 1347 Debio 1348 Debio 1449 Debio 1453 Debio 1454 Debio 1460 Debio 1561 Debio 1562 Debio 8206 SC Debio 8609 Sanvar Debio 9902 - ZT-1 Debiopharm Life Sciences Award Debiovision EPFL EPI-hNE4 FibroTrap fuze H3 Pharma Huperzine-A JCA-Mauvernay Award Moapar Muscular Dystrophy naratuximab emtansine (Debio 1562) Oncology Chair Oxaliplatin PLGA Spinomix Tremelimumab Triptorelin

January 8, 2020

Knight Partners with Debiopharm for the Commercialization of Trelstar® in Canada

November 8, 2019

Debiopharm progresses in their stand against drug-resistant N. gonorrhoeae with extended CARB-X funding of their Debio 1453 antibiotic program

October 9, 2019

A pancreatic and colorectal cancer trial initiated to address the needs of patients with Immune Checkpoint Inhibitor (ICI)-resistant disease by…

September 30, 2019

Debiopharm’s novel IAP antagonist Debio 1143 achieves outstanding Phase II results for high-risk Head and Neck cancer patients

September 3, 2019

Debiopharm successfully completes randomized Phase II study for IAP antagonist Debio 1143 in high risk head & neck cancer patients

July 9, 2019

Debiopharm and BIOASTER join forces to expand research to combat infectious diseases

June 12, 2019

Debiopharm and Ipsen extend their strategic Decapeptyl® (triptorelin) partnership for another 15 years

June 3, 2019

Caris Life Sciences Partners with Debiopharm International SA to Develop Companion Diagnostic for Detection of Rare FGFR Fusions Using Novel…

May 21, 2019

Debiopharm expands its Immuno-Oncology development program for Debio 1143, with the first IAP inhibitor/nivolumab combination trial

First
Previous
1
2
…
23
Next
Last